The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2021 | Ibrutinib as a treatment option for hairy cell leukemia
Kerry Rogers, MD, The Ohio State University, Columbus, OH, shares an update on important clinical data which has implications for the treatment of hairy cell leukemia, a subtype of chronic lymphocytic leukemia (CLL). There is an unmet clinical need in patient populations who cannot tolerate treatment with traditional purine analogues and those with short remission periods. In a cohort of difficult-to-treat patients in a Phase I trial, ibrutinib was found to be associated with an overall response rate of over 50%, an estimated 3-year progression-free survival (PFS) rate of 73%, and a tolerable safety profile in both classical and variant hairy cell leukemia patients. This suggests that ibrutinib may be clinically useful in hairy cell leukemia patients who are unable to receive purine analogue treatment. This interview was conducted during the 2021 virtual international workshop on CLL (iwCLL).
Disclosures
Kerry Rogers, MD, has participated in consultancy work for Acerta Pharma, Pharmacyclics, AbbVie, Genentech, Innate Pharma, and AstraZeneca; has received research funding from Genentech, AbbVie, Novartis, and Janssen; and has received travel funding from AstraZeneca.
